Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

1. San-Miguel, J.
2. Usmani, S.Z.
3. Mateos, M.-V.
4. van de Donk, N.W.C.J.
5. Kaufman, J.L.
6. Moreau, P.
7. Oriol, A.
8. Plesner, T.
9. Benboubker, L.
10. Liu, K.
11. Hellemans, P.
12. Masterson, T.
13. Clemens, P.L.
14. Luo, M.
15. Farnsworth, A.
16. Nahi, H.
17. Chari, A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.3324/HAEMATOL.2019.243790 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus